{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T13:33:54Z","timestamp":1775741634272,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jdiacomp.2026.109309","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T17:10:09Z","timestamp":1773681009000},"page":"109309","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prediction of worsening of renal function by the combination of an initial decline in renal function and blood pressure-lowering effect after renin\u2013angiotensin system blockade in patients with type 2 diabetes mellitus (JDDM 83)"],"prefix":"10.1016","volume":"40","author":[{"given":"Itsuko","family":"Miyazawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin-ichi","family":"Araki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Kume","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Maegawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2026.109309_bb0005","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/jama.2014.18574","article-title":"Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis","volume":"313","author":"Emdin","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.jdiacomp.2026.109309_bb0010","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.2337\/diacare.28.11.2733","article-title":"Development, progression, and regression of microalbuminuria in Japanese patients with type 2 diabetes under tight glycemic and blood pressure control: the Kashiwa study","volume":"28","author":"Yamada","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2026.109309_bb0015","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/S0140-6736(96)10244-0","article-title":"Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group","volume":"349","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.jdiacomp.2026.109309_bb0020","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0168-8227(01)00289-3","article-title":"Effect of captopril or imidapril on the progression of diabetic nephropathy in Japanese with type 1 diabetes mellitus: a randomized controlled study (JAPAN-IDDM)","volume":"55","author":"Katayama","year":"2002","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.jdiacomp.2026.109309_bb0025","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1161\/01.CIR.0000024416.33113.0A","article-title":"Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect","volume":"106","author":"Viberti","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jdiacomp.2026.109309_bb0030","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.2337\/dc06-1998","article-title":"Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes","volume":"30","author":"Makino","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2026.109309_bb0035","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1097\/01.ASN.0000146423.71226.0C","article-title":"Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results","volume":"15","author":"Remuzzi","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jdiacomp.2026.109309_bb0040","article-title":"11. Chronic kidney disease and risk management: standards of care in diabetes-2024","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2026.109309_bb0045","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/ki.2011.79","article-title":"An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function","volume":"80","author":"Holtkamp","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.jdiacomp.2026.109309_bb0050","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1001\/archinte.160.5.685","article-title":"Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?","volume":"160","author":"Bakris","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jdiacomp.2026.109309_bb0055","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/ki.1997.111","article-title":"A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function","volume":"51","author":"Apperloo","year":"1997","journal-title":"Kidney Int"},{"key":"10.1016\/j.jdiacomp.2026.109309_bb0060","article-title":"Serum creatinine elevation after renin-angiotensin system blockade and long term cardiorenal risks: cohort study","volume":"356","author":"Schmidt","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.jdiacomp.2026.109309_bb0065","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1681\/ASN.2006050445","article-title":"Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the reduction of endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial","volume":"18","author":"Eijkelkamp","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jdiacomp.2026.109309_bb0070","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1161\/HYPERTENSIONAHA.118.12060","article-title":"Acute increases in serum creatinine after starting angiotensin-converting enzyme inhibitor-based therapy and effects of its continuation on major clinical outcomes in type 2 diabetes mellitus","volume":"73","author":"Ohkuma","year":"2019","journal-title":"Hypertension"},{"key":"10.1016\/j.jdiacomp.2026.109309_bb0075","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.kint.2016.09.038","article-title":"Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes","volume":"91","author":"Clase","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.jdiacomp.2026.109309_bb0080","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.kint.2016.11.019","article-title":"Acute changes in glomerular filtration rate with renin-angiotensin system (RAS) inhibition: clinical implications","volume":"91","author":"Weir","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.jdiacomp.2026.109309_bb0085","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1159\/000343453","article-title":"Tolerating increases in the serum creatinine following aggressive treatment of chronic kidney disease, hypertension and proteinuria: pre-renal success","volume":"36","author":"Hirsch","year":"2012","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.jdiacomp.2026.109309_bb0090","doi-asserted-by":"crossref","first-page":"709","DOI":"10.2337\/dc13-2023","article-title":"Antihypertensive treatment and resistant hypertension in patients with type 1 diabetes by stages of diabetic nephropathy","volume":"37","author":"Lithovius","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2026.109309_bb0095","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2026.109309_bb0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s101570300000","article-title":"Treatment of diabetic nephropathy with angiotensin II receptor antagonist","volume":"7","author":"Lewis","year":"2003","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.jdiacomp.2026.109309_bb0105","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2026.109309_bb0110","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.2337\/dc08-2297","article-title":"Effects of salt supplementation on the albuminuric response to telmisartan with or without hydrochlorothiazide therapy in hypertensive patients with type 2 diabetes are modulated by habitual dietary salt intake","volume":"32","author":"Ekinci","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2026.109309_bb0115","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1681\/ASN.2007060693","article-title":"Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan","volume":"19","author":"Vogt","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jdiacomp.2026.109309_bb0120","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1681\/ASN.0000000000000426","article-title":"Association between acute declines in eGFR during renin-angiotensin system inhibition and risk of adverse outcomes","volume":"35","author":"Ku","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jdiacomp.2026.109309_bb0125","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/S0140-6736(12)61350-6","article-title":"Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis","volume":"380","author":"Fox","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jdiacomp.2026.109309_bb0130","doi-asserted-by":"crossref","first-page":"S191","DOI":"10.2337\/dc23-S011","article-title":"11. Chronic kidney disease and risk management: standards of care in diabetes-2023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2026.109309_bb0135","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1161\/HYPERTENSIONAHA.118.11944","article-title":"Creatinine rise during blood pressure therapy and the risk of adverse clinical outcomes in patients with type 2 diabetes mellitus","volume":"72","author":"Collard","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.jdiacomp.2026.109309_bb0140","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41371-021-00487-7","article-title":"Acute eGFR declines after intensive BP lowering with RAS blockade and risk of kidney failure","volume":"35","author":"McCallum","year":"2021","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.jdiacomp.2026.109309_bb0145","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2026.109309_bb0150","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1056\/NEJMoa2409183","article-title":"Long-term effects of empagliflozin in patients with chronic kidney disease","volume":"392","author":"Herrington","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2026.109309_bb0155","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S2213-8587(24)00271-7","article-title":"Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials","volume":"13","author":"Badve","year":"2025","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872726000541?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872726000541?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T12:33:26Z","timestamp":1775738006000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872726000541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1056872726000541"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2026.109309","relation":{},"ISSN":["1056-8727"],"issn-type":[{"value":"1056-8727","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prediction of worsening of renal function by the combination of an initial decline in renal function and blood pressure-lowering effect after renin\u2013angiotensin system blockade in patients with type 2 diabetes mellitus (JDDM 83)","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2026.109309","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109309"}}